GLP-1 receptor agonists like Ozempic and Wegovy are reshaping how healthcare systems approach preoperative optimization. Originally developed for diabetes, these therapies are now widely used for weight reduction. In orthopedics, this shift is transforming patient preparation for major surgeries like Total Knee Arthroplasty (TKA).

Historically, orthopedic surgery relied heavily on strict Body Mass Index (BMI) cutoffs to determine surgical eligibility. Hospitals and insurers often mandated weight-loss targets before approving joint replacements, assuming that lower weight equated to lower risk. However, large-scale clinical trials have challenged this assumption. Recent data reveal that rapid, aggressive preoperative weight loss right before a major joint replacement does not automatically mitigate perioperative complications. In fact, arbitrary weight loss can mirror malnutrition, leading to poor wound healing, catabolic states, and higher rates of prosthetic joint infection (PJI).

As adoption of these medications accelerates, orthopedic teams are moving away from static metrics toward dynamic, whole-patient optimization. True surgical readiness must look beyond the number on the scale.

The Peril of Muscle Loss

While GLP-1 therapies deliver meaningful weight reduction, total body weight is only part of the equation. Recent clinical evaluations show that lean muscle mass can account for a substantial percentage of the total weight lost during GLP-1 therapy. This introduces a significant orthopedic challenge. Recovery after major joint surgery depends heavily on functional muscle strength, mobility, and physiologic reserve.

BMI cannot distinguish between fat loss and muscle wasting. If a patient achieves a lower BMI but sacrifices the lean muscle needed for postoperative rehabilitation, we may inadvertently create new recovery risks. Furthermore, drug-induced muscle wasting remains a concern for long-term health; while these medications offer clear short-term metabolic and cardiovascular benefits, maintaining skeletal muscle is a primary predictor of longevity and physical independence in aging populations.

Nutritional and Bone Variables

Reduced appetite and delayed gastric emptying caused by GLP-1 therapies introduce additional preoperative variables. Patients may unintentionally enter surgery in a caloric deficit, experiencing unrecognized micronutrient imbalances or protein deficiencies. Nutrition directly dictates tissue healing and immune response. Without adequate protein intake to support muscle preservation, the surgical timeline can be compromised.

Bone health also requires closer monitoring during rapid pharmacological weight loss. Recent analyses indicate an increased fracture risk among specific populations utilizing GLP-1 therapies, particularly adults older than 67 years and individuals with Class III obesity. For these higher-risk groups, surgical preparation should routinely incorporate bone density assessments, targeted nutritional support, and structured resistance training to safeguard the musculoskeletal foundation.

New Realities in the Operating Room

Beyond long-term recovery, GLP-1 drugs alter immediate perioperative workflows and anesthesia protocols. Because these medications slow digestion, concerns have risen regarding retained gastric contents during sedation, which elevates patient aspiration risks.

To address this, clinical consensus guidelines are evolving. Rather than simply withholding the medication for a week or more preoperatively—which can disrupt glycemic control—current multidisciplinary protocols recommend an extended 24-hour solid-food fast prior to surgery, permitting only clear liquids. Coordinated alignment among surgeons, anesthesiologists, and perioperative teams is essential for safely managing these adjusted fasting windows.

A Comprehensive Approach to Optimization

Pharmacological intervention should never be viewed as a standalone replacement for broader lifestyle engineering. Clinical data indicate that approximately 10% to 14% of patients possess a genetic resistance to GLP-1 drugs, achieving less than a 5% reduction in total weight. For the majority who do respond, the medication functions best as one component of a structured program.

Every GLP-1 treatment plan must pair metabolic management with mandatory resistance training and proactive dietary guidance. The medical community is also tracking next-generation triple-agonist therapies that simultaneously target the GLP-1, GIP, and glucagon receptor pathways. Early data suggest these multi-hormonal approaches may increase resting energy expenditure and offer more muscle-sparing benefits than current options. Future iterations may even serve as targeted bioregulators to decrease systemic inflammation and lower Alzheimer’s risk independent of weight loss.

Ultimately, the fundamental goal of orthopedic care remains unchanged: restoring patient mobility and achieving predictable, long-term functional outcomes. However, the metric for surgical readiness has permanently evolved. By balancing metabolic health with the preservation of lean muscle, proper nutrition, and modernized perioperative protocols, healthcare teams can ensure that patients build a resilient physiological foundation before they ever enter the operating room.

Dr. Tom Meade is an orthopedic total knee replacement specialist at the Lehigh Valley Health Network in Pennsylvania. Dr. Reza Jazayeri is an orthopedic surgeon and the Director of Longevity at the Department of Optimization and Regenerative Medicine at DOCS Health in Los Angeles. [1, 2]